Clinical Evaluation of a COVID-19 Antibody Lateral Flow Assay using Point of Care Samples.
Won LeeSteven StraubeRyan SincicJeanne A NobleJuan Carlos C MontoyAaron E KornblithArun PrakashRalph WangRoland BaintonPhilip KurienPublished in: medRxiv : the preprint server for health sciences (2020)
Humasis® COVID-19 IgG/IgM LFA demonstrates greater than 90% PPV and NPV for samples collected 14 days after the onset of symptoms using samples collected at PoC. While not practical for the diagnosis of acute infection, the use of the lateral flow assays with high specificity may have utility for determining seroprevalence or seroconversion in longitudinal studies.